Expand / Collapse search
Watch TV
Menu

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

Published | Updated

Johnson & Johnson Third-Quarter Sales Top Views

Earnings HQ: FBN’s Lori Rothman breaks down Johnson & Johnson’s third-quarter earnings report. Video

Johnson & Johnson (NYSE:JNJ) reported better than expected quarterly earnings, boosted by surging sales of a new drug for hepatitis C that are expected to evaporate in coming months due to competition from a more potent and convenient combination treatment.

The diversified healthcare company on Tuesday said it earned $4.75 billion, or $1.66 per share, in the third quarter. That compared with $2.98 billion, or $1.04 per share, in the year-earlier period, when J&J took special charges related to legal expenses and merger-related costs.

Excluding special items, J&J earned $1.50 per share. Analysts on average expected $1.45 per share, according to Thomson Reuters I/B/E/S.

Company sales rose 5.1 percent to $18.47 billion, topping the average analyst estimate of $18.38 billion.

J&J said it now expects full-year earnings, excluding special items, of $5.92 to $5.97 per share. In July, it had previously forecast $5.85 to $5.92 per share.